New Data from National Research Center Illuminate Findings in Parkinson's Disease (Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson's disease in experimental animals)
By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators discuss new findings in Parkinson's disease. According to news reporting out of Giza, Egypt, by NewsRx editors, research stated, "Parkinson's disease (PD) affects ~1-2% of the elderly population. Development of a neuroprotective therapy that may be initiated early in the course of the disease to retard/prevent disease progression is highly desirable."
Our news journalists obtained a quote from the research from National Research Center, "This study aimed to investigate prophylactic treatment with coenzyme Q10 (CoQ10) before paraquat (PQ) exposure, a herbicide known to increase the risk for PD, to attain neuroprotection. In addition, therapeutic intervention with CoQ10 in mice already exposed to PQ (24 h) might halt ongoing neurodegeneration and behavioural deterioration. PD was induced experimentally in mice by an injection of PQ (10 mg/kg, intraperitoneal), twice a week for 3 consecutive weeks, either before or after the initiation of treatment with CoQ10 (200 mg/kg). The results of the sustained supplementation with CoQ10, prophylactically and therapeutically, were compared with L-DOPA (100 mg/kg). A battery of behavioural tests was performed, in addition to estimation of protein carbonyl in the brain. CoQ10 elicited a remarkable improvement in most of the behavioural tests and decreased protein carbonyl content in the brain, particularly when it was initiated before rather than after PQ induction of PD."
According to the news editors, the research concluded: "Therefore, CoQ10, which protects against mitochondrial damage, may be beneficial in slowing the progression of PD, particularly when initiated as prophylactic treatment."
For more information on this research see: Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson's disease in experimental animals. Behavioural Pharmacology, 2017;():. (Lippincott Williams and Wilkins - www.lww.com; Behavioural Pharmacology - journals.lww.com/behaviouralpharm/pages/default.aspx)
Our news journalists report that additional information may be obtained by contacting H.N. Attia, Medicinal and Pharmaceutical Chemistry Dept. of (Pharmacology Group), Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt (see also Parkinson's Disease).
Keywords for this news article include: Giza, Egypt, Africa, Movement Disorders, Parkinson's Disease, Enzymes and Coenzymes, Parkinsonian Disorders, Diagnostics and Screening, Brain Diseases and Conditions, Basal Ganglia Diseases and Conditions, Neurodegenerative Diseases and Conditions, Central Nervous System Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC